Biological Safety Testing Products & Services Market to Reach USD 10.20 Billion by 2029 as Biologics and Advanced Therapies Drive Testing Demand

Biological Safety Testing Products & Services Market Overview

The Biological Safety Testing Products & Services Market is entering a strong growth phase as pharmaceutical and biotechnology companies increase the development and commercialization of biologics, vaccines, gene therapies, and other advanced therapeutic products. According to Maximize Market Research, the market was valued at USD 4.03 billion in 2021 and is expected to grow at a CAGR of 12.3% from 2022 to 2029, reaching nearly USD 10.20 billion by 2029.

Biological safety testing plays a critical role in confirming that biological medicines, vaccines, laboratory materials, and healthcare products meet required safety and quality standards. The increasing production of next-generation biologics is a major factor supporting market expansion. Pharmaceutical and biotechnology manufacturers are adopting more sophisticated testing approaches to identify contamination, endotoxins, adventitious agents, bioburden, and other potential risks.

The rising prevalence of chronic diseases is also encouraging investment in biologics and innovative therapeutics. As the pipeline of complex biological products expands, manufacturers require reliable testing throughout research, development, manufacturing, and quality-control processes. Increasing adoption of Good Manufacturing Practices (GMP), stricter regulatory requirements, and greater emphasis on product safety are further supporting demand.

Opportunities are emerging from rapid advances in cell and gene therapy, vaccine development, stem-cell technologies, and personalized medicine. These therapies require specialized safety assessments and characterization, creating demand for advanced testing kits, instruments, laboratory services, and digital testing workflows. The market can also benefit from automation and higher-throughput testing technologies that reduce testing time and improve reproducibility.

* Stay Ahead of Industry Trends: https://www.maximizemarketresearch.com/request-sample/117734/ 

U.S. Market Trends and Investment

The United States remains a major center for biological safety testing because of its large biopharmaceutical industry, extensive research infrastructure, regulatory environment, and concentration of leading testing providers. In 2025, the U.S. Food and Drug Administration announced a plan to reduce, refine, or potentially replace some animal testing requirements for monoclonal antibodies and other drugs by encouraging human-relevant approaches, including AI-based computational models, cell-line testing, and organoid-based toxicity testing. This policy direction is expected to encourage development of alternative safety-testing methodologies and create opportunities for technology providers specializing in advanced biological testing.

The U.S. market is also benefiting from the continued expansion of cell and gene therapy development. The FDA's 2025 draft guidance on postapproval safety and efficacy data for cellular and gene therapy products emphasized the importance of long-term monitoring because of the potentially lasting effects of these therapies. Maravai LifeSciences, one of the companies identified in the MMR report, reported that its Biologics Safety Testing revenue increased 9.9% year over year to USD 16.3 million in the second quarter of 2025, driven by demand for Host Cell Protein qualification services and MockV viral-clearance kits.

Market Segmentation

The Biological Safety Testing Products & Services Market is segmented by Type, Product, Application, and Region.

By product, Reagents & Kits accounted for the largest market share in 2021. The segment benefits from extensive use in research and clinical laboratories, with products including antibodies, biological buffers, freezing and dissociation reagents, and other testing materials. The increasing development of therapeutics and specialized formulations is expected to sustain demand for testing reagents and kits.

By application, Vaccines & Therapeutics held the largest market share in 2021. Stringent safety and efficacy requirements for vaccines and therapeutic products are encouraging manufacturers to conduct comprehensive biological safety testing before commercialization. The continued development of vaccines and innovative biologics is expected to maintain the segment's leading position.

By type, Endotoxin Testing is projected to dominate market growth during the forecast period. Increasing testing requirements in pharmaceutical manufacturing and the availability of multiple endotoxin-testing methodologies are supporting segment expansion.

Biological Safety Testing Products & Services Market Key Players
• Sartorius AG
• Charles River Laboratories International, Inc.
• BSL Bioservice Scientific Laboratories GmbH
• Lonza Group AG
• Milliporesigma
• Sartorius Stedim BioOutsource Limited
• Samsung BioLogics
• Thermo Fisher Scientific
• Merck KGaA
• SGS SA
• WuXi AppTec
• Eurofins Scientific

Competitive Analysis

The MMR report identifies Sartorius AG, Charles River Laboratories International, Inc., BSL Bioservice Scientific Laboratories GmbH, Lonza Group AG, MilliporeSigma, Sartorius Stedim BioOutsource Limited, Samsung BioLogics, Thermo Fisher Scientific, Merck KGaA, SGS SA, WuXi AppTec, and Eurofins Scientific as key companies operating in the market.

The supplied MMR report does not provide individual percentage market shares for the five largest companies; therefore, exact market-share figures are not assigned.

Charles River Laboratories International, Inc. has expanded its biological safety capabilities through testing technologies and services supporting biopharmaceutical development. Its earlier EndoScan-V launch demonstrated the industry's shift toward digitalized endotoxin detection and reporting.

Thermo Fisher Scientific continues to invest in the broader biopharmaceutical ecosystem. In 2025, the company expanded its bioprocessing capabilities in Asia through a new Bioprocess Design Center in Hyderabad and expanded facilities in Korea and Singapore, supporting biologics, vaccine, and cell-and-gene-therapy manufacturing.

Lonza Group AG remains an important biopharmaceutical development and manufacturing partner, with biological safety testing supporting complex biologic and advanced-therapy manufacturing processes.

Sartorius AG continues to focus on technologies supporting biopharmaceutical development, laboratory testing, and quality control, creating opportunities as manufacturers adopt more automated and scalable workflows.

MilliporeSigma benefits from its broad life-sciences portfolio covering laboratory products, analytical technologies, and biopharmaceutical manufacturing solutions, supporting demand for biological safety and quality-control testing.

Regional Analysis

North America dominated the Biological Safety Testing Products & Services Market with a 38.68% share in 2021, according to the MMR report. The region benefits from the presence of major market participants, extensive biopharmaceutical research, increasing investment in cancer research, and strong development activity involving biologics, vaccines, and advanced therapies.

The United States represents the principal growth engine in the region because of its large pharmaceutical and biotechnology sector, established regulatory framework, and significant research and development infrastructure. Regulatory initiatives encouraging advanced safety-testing approaches are also creating opportunities for innovative testing technologies.

The country's growing cell and gene therapy pipeline represents another important opportunity. FDA guidance and regulatory developments around cellular and gene therapies continue to emphasize safety assessment and long-term monitoring, supporting demand for specialized testing services.

Conclusion

The Global Biological Safety Testing Products & Services Market is projected to increase from USD 4.03 billion in 2021 to USD 10.20 billion by 2029, registering a 12.3% CAGR during the forecast period.

In our view, the strongest growth opportunities will come from biologics, vaccines, cell and gene therapies, endotoxin testing, advanced reagents and kits, automated laboratory workflows, and alternative safety-testing technologies.

The transition toward complex biological medicines will require increasingly sophisticated testing throughout development and manufacturing. Companies that combine high-throughput testing, digitalization, automation, advanced analytical technologies, and regulatory expertise will be well positioned to benefit from the market's long-term expansion.

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting firm known for delivering accurate, actionable, and data-driven insights. Our expertise spans diverse industries — including medical devices, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. We provide services such as market-validated forecasts, competitive intelligence, strategic consulting, and industry impact analysis, helping businesses navigate market complexities and achieve sustainable growth.

Contact Maximize Market Research

MAXIMIZE MARKET RESEARCH PVT. LTD.
2nd Floor, Naval IT Park Phase 3,
Pune-Bangalore Highway, Narhe,
Pune, Maharashtra 411041, India.
📞 +91 9607365656
📧 sales@maximizemarketresearch.com